Authors
Latest:
Fezolinetant Changes Menopause Management, with JoAnn Vensko Pinkerton, MDPinkerton reflects on the breakthrough approval for the non-estrogen, non-hormonal daily oral drug earlier this year.
Latest:
SEQUENCE: Comparing Risankizumab to Ustekinumab in Crohn’s DiseaseUstekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.
Latest:
The Future of IgA Nephropathy TreatmentJonathan Barratt, PhD, FRCP, and Brad Rovin, MD, discuss the future of IgAN treatment, highlighting the BlyS/APRIL axis.
Latest:
Assessing Risk and Safety of JAK InhibitorsPanelists discuss the efficacy and safety data for ritlecitinib and deuruxolitinib in treating alopecia areata, highlighting that ritlecitinib achieved SALT scores of ≤20 in 23% of patients at week 24 compared to 1.6% in the placebo group, while deuruxolitinib showed SALT scores of ≤20 in 42.5% (8mg BID ) and 56.8% (12mg BID) of patients, with treatment-emergent adverse events primarily being mild to moderate, including upper respiratory tract infections and headaches for ritlecitinib, and headache and acne for deuruxolitinib.
Latest:
Tips to Optimize Care for Patients With Ulcerative ColitisAdvice for community physicians and gastroenterologists to help manage patients with ulcerative colitis.
Latest:
Risk-Benefit of Geographic Atrophy TreatmentDavid Lally, MD highlights safety signals observed with GA therapies in clinical trials and the future of the treatment landscape.
